1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals

 
• By Derrick Gingery

ANDA approval rates have remained steady, while submission rates dropped compared to prior years.

Generic drugs
The monthly approval rate would be the second-best of the GDUFA era if sustained through the second half of FY 2021. • Source: Alamy

Generic drug submission and full approval rates are nearly equal mid-way through fiscal year 2021, a sign of the steady state the US Food and Drug Administration program is hoping to maintain.

Through March, the FDA reported granting more than 65 full approvals per month, while sponsors submitted about 67 ANDAs per month, according to data posted on 20 April.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

More from Biosimilars & Generics